All In Biotech

Drug Trial Radar · NCT02781727

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

162

Actual

Start

Dec 13, 2016

Primary completion

Jan 17, 2019

Study completion Jan 17, 2019

Sponsor

Sponsor type
Industry
First posted
May 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russia, Turkey, Ukraine, and the United States.

Conditions

  • Growth Hormone Deficiency, Pediatric
  • hGH (Human Growth Hormone)
  • Endocrine System Diseases
  • Hormones
  • Pituitary Diseases

Interventions

  • Once weekly subcutaneous injection of TransCon hGHDrug

    Once weekly subcutaneous injection

  • Once daily subcutaneous injection of GenotropinDrug

    Once daily subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment GroupsTime frame: 52 weeks

Locations

53 sites in 14 countries. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Birmingham, Alabama

  • Ascendis Pharma Investigational Site

    Little Rock, Arkansas

  • Ascendis Pharma Investigational Site

    Los Angeles, California

  • Ascendis Pharma Investigational Site

    Orange, California

  • Ascendis Pharma Investigational Site

    Centennial, Colorado

  • Ascendis Pharma Investigational Site

    Jacksonville, Florida

  • Ascendis Pharma Investigational Site

    Orlando, Florida

  • Ascendis Pharma Investigational Site

    Saint Paul, Minnesota

  • Ascendis Pharma Investigational Site

    Jackson, Mississippi

  • Ascendis Pharma Investigational Site

    Lebanon, New Hampshire

  • Ascendis Pharma Investigational Site

    Mineola, New York

  • Ascendis Pharma Investigational Site

    Oklahoma City, Oklahoma

  • Ascendis Pharma Investigational Site

    Portland, Oregon

  • Ascendis Pharma Investigational Site

    Dallas, Texas

  • Ascendis Pharma Investigational Site

    Fort Worth, Texas

  • Ascendis Pharma Investigational Site

    Tacoma, Washington

  • Ascendis Pharma Investigational Site

    Yerevan, Armenia

  • Ascendis Pharma Investigational Site

    Clayton, Australia

  • Ascendis Pharma Investigational Site

    Minsk, Belarus

  • Ascendis Pharma Investigational Site

    Varna, Bulgaria

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    Athens, Greece

  • Ascendis Pharma Investigational Site

    Milan, Italy

  • Ascendis Pharma Investigational Site

    Roma, Italy

  • Ascendis Pharma Investigational Site

    Grafton, New Zealand

  • Ascendis Pharma Investigatonal Site

    Gdansk, Poland

  • Ascendis Pharma Investigational Site

    Warsaw, Poland

  • Ascendis Pharma Investigational Site

    Iași, Romania

  • Ascendis Pharma Investigational Site

    Izhevsk, Russia

  • Ascendis Pharma Investigational Site

    Kazan', Russia

  • Ascendis Pharma Investigational Site

    Krasnoyarsk, Russia

  • Ascendis Pharma Investigational Site

    Moscow, Russia

  • Ascendis Pharma Investigational Site

    Moscow, Russia

  • Ascendis Pharma Investigational Site

    Nizhny Novgorod, Russia

  • Ascendis Pharma Investigational Site

    Novosibirsk, Russia

  • Ascendis Pharma Investigational Site

    Omsk, Russia

  • Ascendis Pharma Investigational Site

    Saint Petersburg, Russia

  • Ascendis Pharma Investigational Site

    Saint Petersburg, Russia

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.